September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Additive Effect of 0.05% Cyclosporine/0.3% Sodium Hyaluronate Combination Eye Drops in the Treatment of the Dry Eye Disease
Author Affiliations & Notes
  • Guangjin Im
    SamChunDang Pharm, Suwon-si, Korea (the Republic of)
  • Sangjun Park
    SamChunDang Pharm, Suwon-si, Korea (the Republic of)
  • Hohan Yang
    SamChunDang Pharm, Suwon-si, Korea (the Republic of)
  • Yujin Kim
    SamChunDang Pharm, Suwon-si, Korea (the Republic of)
  • Hyeonkyu Go
    Korea Animal Medical Science Institute, Guri, Korea (the Republic of)
  • Hansol Kwon
    Korea Animal Medical Science Institute, Guri, Korea (the Republic of)
  • Myungjin Kim
    Korea Animal Medical Science Institute, Guri, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Guangjin Im, SamChunDang Pharm. (E); Sangjun Park, SamChunDang Pharm. (E); Hohan Yang, SamChunDang Pharm. (E); Yujin Kim, SamChunDang Pharm. (E); Hyeonkyu Go, Korea Animal Medical Science Institute (E); Hansol Kwon, Korea Animal Medical Science Institute (E); Myungjin Kim, Korea Animal Medical Science Institute (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 419. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Guangjin Im, Sangjun Park, Hohan Yang, Yujin Kim, Hyeonkyu Go, Hansol Kwon, Myungjin Kim; Additive Effect of 0.05% Cyclosporine/0.3% Sodium Hyaluronate Combination Eye Drops in the Treatment of the Dry Eye Disease. Invest. Ophthalmol. Vis. Sci. 2016;57(12):419.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cyclosporine and artificial tears are increasingly being combined to treat a plethora of dry eye cases, allowing a 15-minute interval between products. Therefore, we developed a new formulation of twice daily 0.05% cyclosporine/0.3% sodium hyaluronate combination eye drops for patient's convenience and investigated whether the new combination eye drops are more effective than 0.05% cyclosporine and 0.3% sodium hyaluronate.

Methods : Dry eye was induced in C57BL/6 mice through exposure to a controlled environment chamber. To achieve maximum ocular surface dryness, the conditions in controlled environment chamber were supplemented with topical application of 1% atropine twice daily for the first 48 hours. Additionally, the mice also received subcutaneous injections of scopolamine to exacerbate dry eye three times a day for the entire duration of the experiment. Topical formulations containing 0.05% cyclosporine/0.3% sodium hyaluronate combination eye drops, 0.05% cyclosporine, and 0.3% sodium hyaluronate were applied for 21 days following the induction of dry eye. Corneal fluorescein staining (CFS) was performed to detect damage to the cornea at days 0, 7, 14 and 21.

Results : A significant decrease in CFS was observed following topical treatment with 0.05% cyclosporine/0.3% sodium hyaluronate combination eye drops, 0.05% cyclosporine, and 0.3% sodium hyaluronate compared to vehicle treatment at days 7, 14 and 21. Additionally, 0.05% cyclosporine/0.3% sodium hyaluronate combination eye drops showed a statistically significant greater reduction in CFS compared to 0.05% cyclosporine (P < 0.05) at day 7 and 0.05% cyclosporine (P < 0.01) and 0.3% sodium hyaluronate (P < 0.05) at day 21.

Conclusions : Our study shows that 0.05% cyclosporine/0.3% sodium hyaluronate combination eye drops are significantly more efficacious than 0.05% cyclosporine and 0.3% sodium hyaluronate in a dry eye animal model. If their additive effect is confirmed by human clinical trial planned for next year, 0.05% cyclosporine/0.3% sodium hyaluronate combination eye drops can be very helpful to dry eye patients who use 0.05% cyclosporine in combination with sodium hyaluronate.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×